Omega-3脂肪酸和抗氧化剂或可对阿尔兹海默症有疗效
生物谷 · 2015/07/05
防止轻度认知障碍发展最好的方法除了专家建议的身体和精神方面的锻炼,营养也同样重要。依据最新一项研究结果表明,鱼油补充剂和抗氧化剂对治疗阿尔茨海默氏症可能有效。该研究进展对于治疗阿尔茨海默氏病有着潜在的临床意义。


最新一项研究表明,鱼油补充剂和抗氧化剂对治疗阿尔茨海默氏症可能有效。

2015年7月发表在《美国实验生物学学会联合会杂志》上的一篇新文章发现,患有轻度临床认知障碍的病人在认知障碍疾病的早期阶段可观察到β-淀粉样蛋白标志出现了间隙,并在神经组织中减少了炎症的发生。尽管在此项实验中研究了12个病人并且历时达4-17个月,但是调查结果显示这种相对经济且充足的补充剂在进一步临床研究中应该继续进行。

“研究表明,轻度防止认知障碍发展最好的方法除了专家建议的身体和精神方面的锻炼,营养也同样重要。”Milan Fiala说。

为了验证该项研究结果,Fiala和他的同事们在4-17个月内研究了12个轻微认知障碍患者(2位病人只有轻微认知障碍,7位病人确诊患有阿尔茨海默病),观察他们补充omega-3脂肪酸和抗氧化剂的效果。他们通过流式细胞术和显微镜测量了β-淀粉样蛋白的吞噬作用,通过实时荧光定量PCR测定了炎症基因的转录情况,通过酶免疫分析法分析了消散素D1,通过简易精神状态量表分析了患者的认知状况。轻度临床认知障碍的患者的单核细胞β-淀粉样蛋白的吞噬作用从530增加到1306个平均荧光强度单位,而阿尔茨海默氏症患者增加量却并不明显。脂质中介resolvin D1会刺激β-淀粉样蛋白产生体外吞噬作用,80%的轻度临床认知障碍患者巨噬细胞会增加。

“我们用很长一段时间了解了omega-3脂肪酸和一些抗氧化剂有利于人们的健康,也可以保护健康人群,”医学博士Gerald Weissmann说,“现在,我们知道这些补充剂的影响可能扩展到了阿尔茨海默氏症。虽然这些补充剂通常被认为是安全的并且很容易获得,但是全面的临床试验来验证本研究的发现是必要的,并且可用来鉴别哪些人群可能受益更大。”

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment

    We investigated the effects of 4–17 month supplementation with ω-3 fatty acids and antioxidants (Smartfish drink; Smartfish AS, Oslo, Norway) in 12 patients with minor cognitive impairment (MCI) [minimental state examination (MMSE) ≥19], 2 patients with pre-MCI (normal MMSE), and 7 patients with Alzheimer disease (AD) (MMSE <19). We measured the phagocytosis of amyloid-β 1-42 (Aβ) by flow cytometry and microscopy, the transcription of inflammatory genes by RT-PCR, the production of resolvin D1 (RvD1) by enzyme immunoassay, and the cognitive status by MMSE. In patients with MCI and pre-MCI, phagocytosis of Aβ by monocytes increased from 530 to 1306 mean fluorescence intensity units (P = 0.016). The increase in patients with AD was not significant (N.S.). The lipidic mediator RvD1, which stimulates Aβ phagocytosis in vitro, increased in macrophages in 80% of patients with MCI and pre-MCI (mean increase 9.95 pg/ml) (N.S.). Transcription of inflammatory genes’ mRNAs was increased in a subgroup of patients with low transcription at baseline, whereas it was not significantly changed in patients with high transcription at baseline. The mean MMSE score of patients with MCI and pre-MCI was 25.9 at baseline and 25.7 after 4–17 months (N.S.). Our study is the first to show significant immune and biochemical effects of ω-3 fatty acids with antioxidants in patients with MCI. Cognitive benefits of ω-3 supplementation in patients with MCI should be tested in a clinical trial.—Fiala, M., Halder, R. C., Sagong, B., Ross, O., Sayre, J., Porter, V., Bredesen, D. E. ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test